Aims Left ventricular systolic function and presence of heart failure (HF) are important
prognostic factors and dictate future therapeutic strategies after myocardial infarction (MI) …

Heart failure (HF) is a chronic, progressive, and increasingly prevalent syndrome
characterized by stepwise declines in health status and residual lifespan. Despite significant …

There are at least 5 million people in the United States living with chronic heart failure (CHF)
today. 1 Approximately 550 000 new cases of heart failure are identified in this country each …

Background As patients with myocardial infarction (MI) survive for a long time after acute
treatment, it is necessary to pay attention to the prevention of poor prognosis such as heart …

The development of heart failure and/or left ventricular systolic dysfunction has long been
regarded as an ominous complication, significantly increasing the morbidity and short-and …

Left ventricular (LV) remodelling remains an important treatment target in patients after
myocardial infarction (MI) and chronic heart failure (CHF). Accumulating evidence has …

Over the last 50 years, studies investigating the pathogenesis of left ventricular dysfunction
have resulted in many potential therapeutic targets being identified and novel classes of …

INTRODUCTION AND OBJECTIVES: Improvement in the early phase of myocardial
infarction (MI) is associated with a higher rate of late complications, including late-onset …

The pharmacologic management of the patient post myocardial infarction (MI) aims to
achieve several goals. Chief among these is to prevent subsequent events, which include …

BACKGROUND: Major depression (MD) is a key feature in heart failure (HF), and it is
unclear whether common antidepressive medications interact with cardiovascular drugs …